As a result, the EMA have only approved the doublet in BRAF mutant CRC and not the triplet, the FDA have similarly approved the doublet regime alone and the further development of the combination in the first line setting will be as the doublet without MEK inhibition [23]. Here, BRAF is linked to colorectal carcinoma.